El Salvador vs Zambia: Average cost of multi drug-resistant tuberculosis treatment
El Salvador
574 constant 2022 US$
in 2024
Zambia
600 constant 2022 US$
in 2024
El Salvador rank
73rd
Zambia rank
72nd
Average cost of multi drug-resistant tuberculosis treatment over time
- El Salvador
- Zambia
How they compare
Zambia currently reports 600 constant 2022 US$ against 574 constant 2022 US$ in El Salvador, a difference of 26 constant 2022 US$.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Zambia ahead.
El Salvador ranks 73rd and Zambia ranks 72nd of 92 countries.
Zambia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | El Salvador | Zambia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,590 constant 2022 US$ | 5,822 constant 2022 US$ | 4,232 constant 2022 US$ | Zambia |
| 2020s | 3,208 constant 2022 US$ | 3,356 constant 2022 US$ | 147.6 constant 2022 US$ | Zambia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, El Salvador or Zambia?
- Zambia, at 600 constant 2022 US$ against 574 constant 2022 US$ in El Salvador as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between El Salvador and Zambia?
- 26 constant 2022 US$, with Zambia ahead.
- How many years of comparable data are there for El Salvador and Zambia?
- 8 years are reported by both, from 2017 to 2024.
- How do El Salvador and Zambia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- El Salvador ranks 73rd and Zambia ranks 72nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.